Fractyl Health, Inc. (NASDAQ:GUTS) Director Acquires $20,322.54 in Stock

Fractyl Health, Inc. (NASDAQ:GUTS) Director William Bradley purchased 16,129 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was bought at an average price of $1.26 per share, for a total transaction of $20,322.54. Following the acquisition, the director now owns 16,129 shares in the company, valued at $20,322.54. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Fractyl Health Stock Performance

Shares of GUTS stock opened at $1.26 on Thursday. The company’s fifty day simple moving average is $1.62 and its 200-day simple moving average is $2.14. Fractyl Health, Inc. has a 52 week low of $1.16 and a 52 week high of $8.37. The company has a current ratio of 5.58, a quick ratio of 5.57 and a debt-to-equity ratio of 0.60. The company has a market cap of $61.64 million and a PE ratio of -0.10.

Fractyl Health (NASDAQ:GUTS) last issued its earnings results on Monday, March 3rd. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.08). As a group, equities research analysts anticipate that Fractyl Health, Inc. will post -1.61 EPS for the current year.

Hedge Funds Weigh In On Fractyl Health

A number of hedge funds have recently made changes to their positions in GUTS. Jane Street Group LLC purchased a new stake in Fractyl Health during the 3rd quarter worth $25,000. Parkside Financial Bank & Trust purchased a new stake in Fractyl Health during the 4th quarter worth $27,000. Intech Investment Management LLC purchased a new stake in Fractyl Health during the 4th quarter worth $34,000. Raymond James Financial Inc. purchased a new stake in Fractyl Health during the 4th quarter worth $34,000. Finally, JPMorgan Chase & Co. increased its stake in Fractyl Health by 335.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 14,807 shares of the company’s stock worth $37,000 after buying an additional 11,406 shares during the period.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley decreased their price target on shares of Fractyl Health from $18.00 to $10.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.